In recent years, drugs targeting the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) pathways have also investigated in the context of primary and secondary brain tumors. Here, CTLA4 is linked to brain neoplasm.